Our Directors
Aidos Innovations is led by experts in addiction medicine, chemistry, mental health, and care innovation.
Managing Director
Dr. Matthew A. Roberts
Dr. Matthew Roberts, a founder of Aidos Innovations, advances health technologies, leveraging 25+ years’ leadership in biotechnology, life sciences, venture capital, and translational medicine to drive public-good innovation.
Director
Dr. Pouya Azar
Founder and Director of the Azar Lab and IMAPP; Addiction Psychiatrist, Pain Physician, and UBC Assistant Professor focused on opioid use disorder research and treatment innovation.
Director
Prof. Dan Bizzotto
Professor of Chemistry at the University of British Columbia and leading researcher in electrochemical sensor technology.
Director
Dr. Glenn Sammis
Professor of Chemistry at the University of British Columbia specializing in the synthesis and development of pharmaceuticals.
Director
Dr. Jesse Sidhu
Physician leader, overseeing hospital-based mental health and substance use services in Vancouver.
Making Addiction History
WHO WE ARE
Aidos is a nonprofit institute translating science into solutions that help those suffering from substance use disorder, return to healthy productive lives in their community.
Our mission is to turn cutting-edge science into accessible tools, therapies, and technologies that support patients, physicians, and those on the front lines of substance use disorder.
Our research portfolio spans diagnostic tools, digital recovery technologies, forensic applications, and advanced therapeutics, all structured into short-, medium-, and long-term impact horizons.
Our mission is to turn cutting-edge science into accessible tools, therapies, and technologies that support patients, physicians, and those on the front lines of substance use disorder.
Our research portfolio spans diagnostic tools, digital recovery technologies, forensic applications, and advanced therapeutics, all structured into short-, medium-, and long-term impact horizons.
OUR FOCUS
Opioid Use Detection
Portable, ultra-sensitive technologies that detect and quantify opioid presence for faster treatment and overdose prevention.
Digital Therapeutics
AI-powered platforms that support personalized, long-term recovery through smart data integration and behavioral insights.
Track & Trace
Molecular labeling innovations that help identify and intercept illicit opioids while safeguarding legitimate medical use.
Novel Therapeutics
Developing non-opioid pain solutions and next-gen medications to reduce cravings, improve outcomes, and restore lives.
OUR PARTNERS
WHY WE EXIST
Our work is rooted in clinical excellence, scientific rigor, and compassionate care. We are focused on the best solutions science has to offer, and are choiceful in which technologies we invest in, which offer the greatest chance to help those who suffer from substance use disorder and to those who care for them. We are grateful to the donors that have contributed to Aidos and all our collective institutions that make our work possible.
Aidos exists at the intersection of science and human need. We translate science into solutions. Our goal is not just to advance research, but to rapidly translate it into outcomes that change lives.
— MATTHEW A. ROBERTS, MANAGING DIRECTOR